Updated Jul 16, 2026
Mazumdar Claire has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $2.55M.
Claire Mazumdar is the Chief Executive Officer and Director of Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. She has been involved in the company's strategic direction and operations.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-14 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 28 | $29.68 | $831 |
| 2026-07-14 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 10.0K | $28.42 | $283K |
| 2026-07-14 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 10.0K | $3.79 | $38K |
| 2026-05-20 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 3.0K | $20.35 | $61K |
| 2026-05-20 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 12.0K | $19.96 | $240K |
| 2026-05-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 15.0K | $3.79 | $57K |
| 2026-04-20 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 15.0K | $23.61 | $354K |
| 2026-04-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 15.0K | $3.79 | $57K |
| 2026-04-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 7.1K | $5.45 | $39K |
| 2026-04-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 7.5K | $3.79 | $28K |
| 2026-04-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 8.2K | $4.44 | $36K |
| 2026-03-20 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 1.6K | $18.95 | $30K |
| 2026-03-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 1.6K | $3.79 | $6K |
| 2026-03-20 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 6.9K | $18.78 | $130K |
| 2026-03-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 6.9K | $3.79 | $26K |
| 2026-03-20 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 6.5K | $18.84 | $122K |
| 2026-03-20 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 6.5K | $3.79 | $25K |
| 2026-03-11 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 36.8K | $19.17 | $705K |
| 2026-03-11 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 36.8K | $3.79 | $139K |
| 2026-03-07 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 3.8K | $18.75 | $72K |
Claire Mazumdar is the Chief Executive Officer and Director of Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. She has been involved in the company's strategic direction and operations.…
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($2.55M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Mazumdar Claire profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.